Skip to main content

Table 5 Market share of the alternative treatments

From: Costs and effects of paliperidone extended release compared with alternative oral antipsychotic agents in patients with schizophrenia in Greece: A cost effectiveness study

Comparators

Market share in units (%)

Source

Paliperidone ER

0.0

Not yet marketed

Risperidone

42.0

http://www.imshealth.com

Olanzapine

34.4

http://www.imshealth.com

Quetiapine

14.1

http://www.imshealth.com

Ziprasidone

4.7

http://www.imshealth.com

Aripiprazole

4.8

http://www.imshealth.com

Back to article page

Annals of General Psychiatry

ISSN: 1744-859X